NeuroOne Medical Technologies Corporation (NMTC) Stock

NeuroOne Medical Technologies Corporation (NMTC) is a Healthcare stock trading at $2.15 (as of 2026-08-20), with a market capitalization of $19.58M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

NeuroOne Medical Technologies Corporation develops and commercializes medical technology including thin film electrode systems for continuous EEG and stereo-EEG recording, as well as applications involving spinal cord stimulation, brain stimulation, and ablation. Its products are intended for patients with neurological conditions such as epilepsy and movement or pain disorders.

Understand NeuroOne Medical Technologies Corporation: how it makes money

NeuroOne develops and commercializes thin film electrode and related neurological technologies, including systems for continuous EEG (cEEG, sEEG) and a OneRF radio frequency ablation approach, and it monetizes through product sales as well as license and collaboration payments.

Because the company’s revenue is tied to commercialization milestones, turning clinical and center adoption of its OneRF ablation system into product revenue, while also relying on license and one-time collaboration payments, determines whether it can move from early activity to recurring commercial dollars.

Business quality (Weak): The company shows ongoing clinical and adoption progress for OneRF, but the latest reported period shows 0.0B revenue and a sharply negative operating margin, so scale and revenue recognition remain key uncertainties.

Bull case

Center adoption is progressing for OneRF, with OneRF Ablation System placements in epilepsy centers: The latest operating snapshot shows OneRF Ablation System Placed in Epilepsy Centers at 5.0, and Patients Successfully Implanted with OneRF Ablation System at 16.0.
The company tracks technical and regulatory readiness, supporting the commercialization story: It reports Issued and Pending Patents in the United States (13.0) and Issued and Pending Patents Internationally (4.0), alongside activity metrics such as RF Electrodes Implanted (200.0) and RF Ablations Performed (50.0).

Bear case

Revenue and profitability visibility are weak in the most recent reported period: For the period ended 2026-03-31, reported revenue was 0.0B and operating margin was -128.7%.
The operating footprint appears early, with limited launch scale implied by the rollout metrics: Key commercialization metrics include Number of RF Ablations Performed (Limited Launch) at 150.0 and OneRF Ablation System Placed in Epilepsy Centers at 5.0, indicating the business is not yet broad-based.

Valuation — source: SEC EDGAR (first-party)
Price	$2.15
Market Cap	$19.58M
Price / Book	5.20
Price / Sales	2.28
FCF Yield	-91.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$9.10M
Net Margin	-39.6%
Revenue Growth (YoY)	16.3%
EPS Growth (YoY)	666.7%
FCF Growth (YoY)	306.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	7.75 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Medical Equipment)	32.9

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Bleichroeder LP ($3.11M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	David A. Rosa
Employees	17
Country	US
IPO Date	2018-03-15

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.